Evidence map›Paper›PMID 37419566›Full record

ArticleThe lancet. HIV2023

Long-acting antiretrovirals: research and implementation considerations in Africa.

Claire Norcross, Loice Achieng Ombajo, Sheetal Kassim, Nigel Garrett, Fiona V Cresswell, Eugene Ruzagira

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in The lancet. HIV, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Claire NorcrossDepartment of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: claire.norcross@lshtm.ac.uk.
Loice Achieng OmbajoDepartment of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, Kenya; Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya.
Sheetal KassimDesmond Tutu Health Foundation, Cape Town, South Africa; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Nigel GarrettCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.
Fiona V CresswellDepartment of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK; Global Health & Infection Department, Brighton & Sussex Medical School, Brighton, UK; Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
Eugene RuzagiraMedical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.

Funding

Medical Research Council MC_UU_00033/1Medical Research Council MR/K019708/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-HIV AgentsHIV InfectionsAfricaAnti-Retroviral AgentsHumansAnti-HIV AgentsAnti-Retroviral Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.